|
| Press Releases |
|
 |
|
| Tuesday, July 27, 2021 |
|
|
Biogen and Eisai Announce ADUHELM (aducanumab-avwa) Data Presentations at Alzheimer's Association International Conference 2021 |
| Biogen (Nasdaq: BIIB) and Eisai Co., Ltd. (Tokyo, Japan) today announced that Biogen, as part of its Alzheimer's disease (AD) research portfolio, will contribute four virtual posters that showcase data from its clinical trials with ADUHELMTM (aducanumab-avwa) injection 100 mg/mL solution at the AAIC. more info >> |
|
| Friday, July 23, 2021 |
|
|
Eisai: FDA Approves LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) Combination for Patients With Certain Types of Advanced Endometrial Carcinoma |
| Study Results Demonstrated Statistically Significant Improvements in Overall Survival, Progression-Free Survival and Overall Response Rate, Helping to Address a Significant Unmet Need in Advanced Endometrial Carcinoma. more info >> |
|
| Wednesday, July 21, 2021 |
|
|
Eisai to Present Latest Data on Pipeline Assets in The Area of Alzheimer's Disease and Dementia at AAIC 2021 |
| Eisai Co., Ltd. announced today that the company will conduct a total of 11 presentations, including the latest data of the investigational anti-amyloid beta (Abeta) protofibril antibody lecanemab (development code: BAN2401) for which the U.S. Food and Drug Administration has granted Breakthrough Therapy designation, at the Alzheimer's Association International Conference (AAIC). more info >> |
|
| Monday, July 19, 2021 |
|
|
Eisai Launchs Bile Acid Transporter Inhibitor Goofice in Thailand |
| Eisai Co., Ltd. announced that its Thailand subsidiary Eisai (Thailand) Marketing Co., Ltd. has launched the bile acid transporter inhibitor Goofice (generic name: elobixibat hydrate) in Thailand. more info >> |
|
| Thursday, July 1, 2021 |
|
|
Eisai Launches In-house Developed Anti-insomnia Drug Dayvigo (Lemborexant) In Hong Kong |
| Eisai Co., Ltd. announced today that its Hong Kong subsidiary Eisai (Hong Kong) Co., Ltd. has launched the in-house-discovered and developed orexin receptor antagonist DAYVIGO (generic name: lemborexant) for the treatment of adults with insomnia, characterized by difficulties with sleep onset and/or sleep maintenance. more info >> |
|
| Thursday, June 24, 2021 |
|
|
Eisai and Biogen Inc. Announce U.S. FDA Grants Breakthough Therapy Designation for Lecanemab (BAN2401) |
| Eisai Co., Ltd. and Biogen Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthough Therapy designation for lecanemab (BAN2401), an investigational anti-amyloid beta (Abeta) protofibril antibody for the treatment of Alzheimer's disease (AD). more info >> |
|
| Wednesday, June 23, 2021 |
|
|
Anticancer Agent "Tazverik Tablets 200mg" (Tazemetostat Hydrobromide) Approved In Japan For EZH2 Gene Mutation-positive Follicular Lymphoma |
| Eisai Co., Ltd. announced today that it has obtained manufacturing and marketing approval for the EZH2 inhibitor "Tazverik Tablets 200 mg" (tazemetostat hydrobromide) in Japan with the indication of relapsed or refractory EZH2 gene mutation-positive follicular lymphoma (only when standard treatment is not applicable). more info >> |
|
| Friday, June 18, 2021 |
|
|
Eisai, Bristol Myers Squibb Enter Into Global Strategic Collaboration for Eisai's MORAb-202 Antibody Drug Conjugate |
| Eisai Co., Ltd. and Bristol-Myers Squibb Company announced today that the companies have entered into an exclusive global strategic collaboration agreement for the co-development and co-commercialization of MORAb-202, an antibody drug conjugate (ADC). more info >> |
|
| Tuesday, June 15, 2021 |
|
|
Eisai to Divest Rights for Zonegran in Europe and Other Regions to Advanz Pharma |
| Eisai Co., Ltd. announced today that it has entered into an agreement to divest its rights for the antiepileptic agent Zonegran (generic name: zonisamide) in Europe, the Middle East, Russia, and Australia to Advanz Pharma. more info >> |
|
| Wednesday, June 9, 2021 |
|
|
Eisai Receives Special Prize at Platinum Career Award 2021 |
| Eisai Co., Ltd. announced today that it has received a special prize at the Platinum Career Award 2021. The awards ceremony was held via online at the symposium on June 8, 2021. more info >> |
|
|
|
|
|
|
|
|
 |
| Latest Press Releases |
|
Sharp Wins IAM's "Asia IP Elite 2025", Awarded to Companies with Outstanding Intellectual Property Strategy for The Second Consecutive Year
Nov 28, 2025 18:36 JST
|
|
|
Fujitsu builds platform for NSK to create environmental value throughout the product lifecycle of bearing products
Nov 28, 2025 18:01 JST
|
|
|
Fujitsu launches Japan Edition of SAP Fioneer Cloud for Insurance, a next-generation platform supporting core business operations in the Japanese insurance industry
Nov 28, 2025 17:28 JST
|
|
|
Edvantage Group Announces FY2025 Annual Results
Nov 28, 2025 13:00 HKT/SGT
|
|
|
Magnolia Welcomes Tech Pioneer Luc Haldimann as New Board Chairman to Expand Global Growth and AI Strategy
Nov 28, 2025 00:00 HKT/SGT
|
|
|
NEC Launches Sales Support Solution Utilizing Agentic AI
Nov 27, 2025 22:31 JST
|
|
|
Fujitsu and Yamaguchi University develop low-power edge computing technology for near real-time image processing on small satellites
Nov 27, 2025 22:00 JST
|
|
|
Tat Hong Equipment Service Co., Ltd. Announces 2025/26 Interim Results
Nov 27, 2025 18:43 HKT/SGT
|
|
|
PLN Collaborates with Norwegian and Japanese Stakeholders to Advance High-Integrity Cross-Border Carbon Markets at COP30 
Nov 27, 2025 18:30 HKT/SGT
|
|
|
Geespace Accelerates Global Expansion as GEESATCOM Enters New Markets
Nov 27, 2025 15:30 HKT/SGT
|
|
|
KEF, the premium speaker brand of Gold Peak, partners with Huawei to unlock new wireless high-fidelity experience with HUAWEI HiPlay
Nov 27, 2025 13:29 HKT/SGT
|
|
|
World's first ever spiral escalator renewal project conducted at a commercial facility in Mexico
Nov 27, 2025 11:00 JST
|
|
|
CBL International Limited Wins Prestigious 'CGMA Excellent Sustainability Award' at the CGMA Annual Awards 2025
Nov 26, 2025 18:54 HKT/SGT
|
|
|
Eisai Completes Rolling Submission to US FDA for LEQEMBI(R) IQLIK(TM) (lecanemabirmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease Under Fast Track Status
Nov 26, 2025 19:42 JST
|
|
|
Fujitsu accelerates blue carbon certification with ocean digital twin technology
Nov 26, 2025 19:05 JST
|
|
|
|
|
More Press release >> |
|
|
|
|
|
|
|
